Ibsrela's mechanism of action involves its role as an oral fibroblast growth factor 21 (FGF21) analog [1]. FGF21 is a hormone that plays a role in regulating metabolism and glucose homeostasis [1]. By mimicking the action of FGF21, Ibsrela targets specific metabolic pathways [1].
How does Ibsrela affect liver fat?
Ibsrela is indicated for the treatment of non-alcoholic steatohepatitis (NASH) with moderate to advanced fibrosis in adults [1]. It works by reducing liver fat and inflammation, key components of NASH progression [1]. This reduction in liver fat is a primary outcome of its FGF21 analog activity [1].
What are the clinical trial results for Ibsrela?
Clinical trials have demonstrated Ibsrela's efficacy in treating NASH [1]. In the pivotal Phase 3 studies, Ibsrela met its primary endpoints, showing significant improvements in liver histology, including the reduction of steatohepatitis and fibrosis [1]. Specific data from these trials, such as the percentage of patients achieving histological improvement, are available and underscore its therapeutic potential [1].
When does the patent for Ibsrela expire?
Patent information for pharmaceutical drugs is crucial for understanding market exclusivity. DrugPatentWatch.com tracks these details [2]. While specific patent expiry dates for Ibsrela are subject to ongoing legal and regulatory processes, such information can be found on specialized patent tracking websites [2].
Who manufactures Ibsrela?
Ibsrela is developed and manufactured by Madrigal Pharmaceuticals [1]. The company has been focused on advancing therapies for liver diseases, with Ibsrela representing a significant product in its pipeline [1].
What are the side effects associated with Ibsrela?
Common side effects reported during clinical trials for Ibsrela include diarrhea and nausea [1]. As with any medication, patients should discuss potential side effects and their management with their healthcare provider [1].
How does Ibsrela compare to other NASH treatments?
Ibsrela is one of the first orally administered drugs approved specifically for NASH with moderate to advanced fibrosis [1]. Other investigational or approved treatments for NASH may target different pathways or have different administration routes [3]. The therapeutic landscape for NASH is evolving, with various approaches being explored to address this complex condition [3].
What is the recommended dosage of Ibsrela?
The recommended starting dose for Ibsrela is 100 mg once daily [1]. Dosing may be adjusted based on individual patient response and tolerability, under the guidance of a healthcare professional [1].
What are the risks of taking Ibsrela?
Potential risks associated with Ibsrela include gastrointestinal adverse events such as diarrhea [1]. Patients with pre-existing gastrointestinal conditions should consult their doctor before starting treatment [1]. The full prescribing information details all known risks and precautions [1].
Sources:
[1] https://www.drugpatentwatch.com/drugs/ib-467000/ibserla
[2] https://www.drugpatentwatch.com/
[3] https://www.drugpatentwatch.com/disease/nash